CLDQ Bibliography

  1. Younossi ZM, Nader F, Labriola D, Taub R, Racila A, Henry L, Stepanova M. Self-Reported Cognitive Function in Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom Trials. J Clin Exp Hepatol. 2026 Jul- Aug;16(4):103531. doi: 10.1016/j.jceh.2026.103531. Epub 2026 Mar PMID: 41953252; PMCID: PMC13054080.
  2. Younossi ZM, Stepanova M, Younossi I, Racila A. Development and Validation of a Symptom-Based Patient-Reported Outcome Measure for MASH: The CLDQ-MASH Symptom Questionnaire (CLDQ-MASH-SQ). Am J Gastroenterol. 2026 Jul doi: 10.14309/ajg.0000000000004171. Epub ahead of print. PMID: 42536024.
  3. Yilmaz Y, Yu ML, Alswat K, El-Kassas M, Ferret MB, Papatheodoridis G, Fernandez M, Eguchi Y, Duseja A, Keklikkiran Ç, Hamid S, Chan WK, Gordon SC, Esmat G, Isakov V, Roberts S, Méndez-Sánchez N, Fan JG, Gomez MR, George J, Singal AK, Ahmed A, Lam B, Nader F, Henry L, Stepanova M, AlQahtani S, Younossi ZM; Global Liver Council. Impact of Fatigue on Patient-Reported Outcomes and Work Productivity in Chronic Hepatitis B and C: Insights From a Multinational Registry Study. J Viral Hepat. 2026 Jun;33(6):e70188. doi: 10.1111/jvh.70188. PMID: 42144799.
  4. Younossi ZM, Stepanova M, Younossi I, deAvila L. Development and validation of a disease-specific health-related quality of life questionnaire for alcohol- associated liver disease: The CLDQ-ALD. Hepatol Commun. 2026 May 26;10(6):e0963. doi: 10.1097/HC9.0000000000000963. PMID: 42190270; PMCID: PMC13209475.
  5. Younossi ZM, Nader F, Labriola D, Taub R, Racila A, Henry L, Stepanova M. Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis. Hepatol Commun. 2026 Feb 26;10(3):e00913. doi: 10.1097/HC9.0000000000000913. PMID: 41758054; PMCID: PMC12947990.
  6. Younossi ZM, Stepanova M, Schattenberg JM, Henry L. Measuring health-related quality of life and patient-reported outcomes in chronic liver disease. J Hepatol. 2026 Feb;84(2):457-472. doi: 10.1016/j.jhep.2025.09.027. Epub 2025 Oct PMID: 41072803.
  7. Levy C, Younossi ZM, Mayo MJ, Kremer AE, Pate J, Ieyoub J, Zincavage R, Padilla B, Ito D, Perez CFM. Assessment of PBC Pruritus From the ITCH-E Study: Quality of Life, Productivity, and Treatment Experiences. Liver Int. 2025 Sep;45(9):e70276. doi: 10.1111/liv.70276. PMID: 40847640; PMCID: PMC12374225.
  8. Younossi ZM, Stepanova M, Racila A, Henry L, Labriola D, Taub R, Nader F. Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology. 2025 Apr 1;81(4):1318-1327. doi: 10.1097/HEP.0000000000001084. Epub 2024 Sep PMID: 39250515.
  9. Younossi ZM, Stepanova M, Kim Y, Dodge S, Labriola D, Taub R, Nader F. Assessments of Health Utilities in Patients With Metabolic Dysfunction- Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D Instruments. Gastro Hep Adv. 2025 Feb 7;4(6):100642. doi: 10.1016/j.gastha.2025.100642. PMID: 40692819; PMCID: PMC12277723.
  10. Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH). JHEP Rep. 2024 Nov 16;7(3):101276. doi: 10.1016/j.jhepr.2024.101276. PMID: 39980748; PMCID: PMC11835563.
  11. Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of a Primary Biliary Cholangitis-Specific Version of Chronic Liver Disease Questionnaire: CLDQ-PBC. Clin Transl Gastroenterol. 2024 Sep 1;15(9):e1. doi: 10.14309/ctg.0000000000000709. PMID: 38738764; PMCID: PMC11421712.
  12. Alqahtani SA, Yilmaz Y, El-Kassas M, Alswat K, Sanai F, AlZahrani M, Abaalkhail F, AlShaikh M, Al-Hamoudi WK, Nader F, Stepanova M, Younossi ZM; Global NASH Council. Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt. J Viral Hepat. 2024 Jun;31(6):300-308. doi: 10.1111/jvh.13935. Epub 2024 Apr PMID: 38622910.
  13. Younossi ZM, AlQahtani SA, Funuyet-Salas J, Romero-Gómez M, Yilmaz Y, Keklikkiran C, Alswat K, Yu ML, Liu CJ, Fan JG, Zheng MH, Burra P, Francque SM, Castera L, Schattenberg JM, Newsome PN, Allen AM, El-Kassas M, Treeprasertsuk S, Hameed S, Wai-Sun Wong V, Zelber-Sagi S, Takahashi H, Kawaguchi T, Castellanos Fernández MI, Duseja A, Arrese M, Rinella M, Singal AK, Gordon SC, Fuchs M, Eskridge W, Alkhouri N, Cusi K, Loomba R, Ranagan J, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Gerber L, Lam B, Fornaresio L, Nader F, Spearman CW, Roberts SK, Chan WK, Silva M, Racila A, Golabi P, Ananchuensook P, Henry L, Stepanova M, Carrieri P, Lazarus JV; Global NASH Council. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Rep. 2024 Mar 12;6(7):101066. doi: 10.1016/j.jhepr.2024.101066. Erratum in: JHEP Rep. 2025 Feb 17;7(3):101359. doi: 10.1016/j.jhepr.2025.101359. PMID: 39022387; PMCID: PMC11252535.
  14. Younossi ZM, Stepanova M, Myers RP, Younossi I, Henry L. The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression. Clin Gastroenterol Hepatol. 2023 Apr;21(4):970-977.e1. doi: 10.1016/j.cgh.2022.04.023. Epub 2022 May PMID:
  15. Younossi ZM, Yu ML, Yilmaz Y, Alswat KA, Buti M, Fernandez MIC, Papatheodoridis G, Hamid SS, El-Kassas M, Chan WK, Duseja AK, Gordon SC, Eguchi Y, Isakov VA, Roberts SK, Fan JG, Singal AK, Romero-Gómez M, Ahmed A, Ong J, Lam BP, Younossi I, Nader F, Racila A, Stepanova M, Alqahtani S. Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™. J Viral Hepat. 2023 Apr;30(4):335-344. doi: 10.1111/jvh.13800. Epub 2023 Jan PMID: 36601668.
  16. Younossi ZM, Stepanova M, Younossi I, Racila A. Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC. Hepatol Commun. 2023 Feb 1;7(2):e0049. doi: 10.1097/HC9.0000000000000049. PMID: 36724122; PMCID: PMC9894344.
  17. Yilmaz Y, Toraman AE, Alp C, Doğan Z, Keklikkiran C, Stepanova M, Younossi Z. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. Aliment Pharmacol Ther. 2023 Jan;57(2):215-223. doi: 10.1111/apt.17301. Epub 2022 Nov PMID: 36369643.
  18. Younossi ZM, Yu ML, El-Kassas M, Esmat G, Castellanos Fernández MI, Buti M, Papatheodoridis G, Yilmaz Y, Isakov V, Duseja A, Méndez-Sánchez N, Hamid S, Gordon SC, Romero-Gómez M, Chan WK, Ong JP, Younossi I, Lam B, Ziayee M, Nader F, Racila A, Henry L, Stepanova M; Global NASH Council™. Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry. J Viral Hepat. 2022 Nov;29(11):1015-1025. doi: 10.1111/jvh.13741. Epub 2022 Sep PMID: 36036096.
  19. Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, Augusto M, Nair S. The burden of non-alcoholic steatohepatitis: A systematic review of health- related quality of life and patient-reported outcomes. JHEP Rep. 2022 Jun 15;4(9):100525. doi: 10.1016/j.jhepr.2022.100525. PMID: 36039144; PMCID: PMC9418497.
  20. Younossi ZM, Racila A, Muir A, Bourliere M, Mangia A, Esteban R, Zeuzem S, Colombo M, Manns M, Papatheodoridis GV, Buti M, Chokkalingam A, Gaggar A, Nader F, Younossi I, Henry L, Stepanova M. Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. Clin Gastroenterol Hepatol. 2022 Feb;20(2):438-446. doi: 10.1016/j.cgh.2021.01.026. Epub 2021 Jan PMID: 33493697.
  21. Younossi ZM, Stepanova M, Noureddin M, Kowdley KV, Strasser SI, Kohli A, Ruane P, Shiffman ML, Sheikh A, Gunn N, Caldwell SH, Huss RS, Myers RP, Wai-Sun Wong V, Alkhouri N, Goodman Z, Loomba R. Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Hepatol Commun. 2021 May 12;5(7):1201-1211. doi: 10.1002/hep4.1710. PMID: 34278169; PMCID: PMC8279457.
  22. Castellanos-Fernández MI, Borges-González SA, Stepanova M, Infante-Velázquez ME, Ruenes-Domech C, González-Suero SM, Dorta-Guridi Z, Arus-Soler ER, Racila A, Younossi ZM. Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience. Ann Hepatol. 2021 May-Jun;22:100277. doi: 10.1016/j.aohep.2020.10.005. Epub 2020 Oct PMID: 33130334.
  23. Buti M, Stepanova M, Palom A, Riveiro-Barciela M, Nader F, Roade L, Esteban R, Younossi Z. Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. JHEP Rep. 2021 Mar 17;3(3):100280. doi: 10.1016/j.jhepr.2021.100280. Erratum in: JHEP Rep. 2022 Jul 20;4(9):100526. doi: 10.1016/j.jhepr.2022.100526. PMID: 34041466; PMCID: PMC8141931.
  24. Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2021 Mar;36(3):629-636. doi: 10.1111/jgh.15172. Epub 2020 Jul PMID: 32627871.
  25. Younossi ZM, Stepanova M, Younossi I, Racila A. Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV. J Viral Hepat. 2021 Mar;28(3):484-492. doi: 10.1111/jvh.13451. Epub 2020 Dec PMID: 33306234.
  26. Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanoue T, Trauner M, Goodman Z, Harrison SA. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2019 Nov;17(12):2552-2560.e10. doi: 10.1016/j.cgh.2019.02.024. Epub 2019 Feb PMID: 30779990.
  27. Younossi ZM, Stepanova M, Lawitz EJ, Reddy KR, Wai-Sun Wong V, Mangia A, Muir AJ, Jacobson I, Djedjos CS, Gaggar A, Myers RP, Younossi I, Nader F, Racila A. Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. Am J Gastroenterol. 2019 Oct;114(10):1636-1641. doi: 10.14309/ajg.0000000000000375. PMID: 31464743.
  28. Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F. Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Liver Int. 2019 Oct;39(10):1837-1844. doi: 10.1111/liv.14171. Epub 2019 Jul PMID: 31173468.
  29. de Avila L, Weinstein AA, Estep JM, Curry MP, Golabi P, Escheik C, Birerdinc A, Stepanova M, Gerber L, Younossi ZM. Cytokine balance is restored as patient- reported outcomes improve in patients recovering from chronic hepatitis C. Liver Int. 2019 Sep;39(9):1631-1640. doi: 10.1111/liv.14115. Epub 2019 May PMID:
  30. Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy- Proven Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2019 Sep;17(10):2093-2100.e3. doi: 10.1016/j.cgh.2019.01.001. Epub 2019 Jan PMID:
  31. Younossi ZM, Stepanova M, Reddy R, Manns MP, Bourliere M, Gordon SC, Schiff E, Tran T, Younossi I, Racila A. Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C. Liver Int. 2019 Jan;39(1):54-59. doi: 10.1111/liv.13900. Epub 2018 Jul PMID:
  32. Younossi ZM, Stepanova M, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Younossi I, Racila A. Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1641-1649.e6. doi: 10.1016/j.cgh.2018.02.037. Epub 2018 Mar PMID:
  33. Younossi ZM, Stepanova M, Lawitz E, Charlton M, Loomba R, Myers RP, Subramanian M, McHutchison JG, Goodman Z. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018 Oct;38(10):1849-1859. doi: 10.1111/liv.13706. Epub 2018 Feb PMID: 29377462.
  34. Stepanova M, Nader F, Bureau C, Adebayo D, Elkrief L, Valla D, Peck- Radosavljevic M, McCune A, Vargas V, Simon-Talero M, Cordoba J, Angeli P, Rossi S, MacDonald S, Capel J, Jalan R, Younossi ZM. Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. Qual Life Res. 2018 Jun;27(6):1513-1520. doi: 10.1007/s11136-018-1813-8. Epub 2018 Feb PMID:
  35. Stepanova M, Younossi I, Racila A, Younossi ZM. Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). Value Health. 2018 May;21(5):612-621. doi: 10.1016/j.jval.2017.10.005. Epub 2017 Dec PMID:
  36. Younossi ZM, Stepanova M, Gordon S, Zeuzem S, Mann MP, Jacobson I, Bourliere M, Cooper C, Flamm S, Reddy KR, Kowdley K, Younossi I, Hunt S. Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. Clin Gastroenterol Hepatol. 2018 Apr;16(4):567-574.e6. doi: 10.1016/j.cgh.2017.11.023. Epub 2017 Nov PMID: 29155352.
  37. Stepanova M, Thompson A, Doyle J, Younossi I, de Avila L, Younossi ZM. Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens. J Infect Dis. 2018 Mar 13;217(7):1033-1043. doi: 10.1093/infdis/jix681. PMID: 29293991.
  38. Younossi ZM, Stepanova M, Jacobson IM, Asselah T, Gane EJ, Lawitz E, Foster GR, Roberts SK, Thompson AJ, Willems BE, Welzel TM, Pearlman B, Younossi I, Racila A, Henry L. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and Aliment Pharmacol Ther. 2018 Jan;47(2):259-267. doi: 10.1111/apt.14423. Epub 2017 Nov PMID: 29181842.
  39. Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient- reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. Liver Int. 2017 Dec;37(12):1796-1804. doi: 10.1111/liv.13462. Epub 2017 May PMID: 28470938.
  40. Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, Hunt S. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 2017 Aug;37(8):1209-1218. doi: 10.1111/liv.13391. Epub 2017 Mar PMID: 28211165.
  41. Weinstein AA, Diao G, Baghi H, Escheik C, Gerber LH, Younossi ZM. Demonstration of two types of fatigue in subjects with chronic liver disease using factor analysis. Qual Life Res. 2017 Jul;26(7):1777-1784. doi: 10.1007/s11136-017-1516-6. Epub 2017 Feb PMID: 28224256.
  42. Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Henry L, Hunt S. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat. 2016 Nov;23(11):857-865. doi: 10.1111/jvh.12554. Epub 2016 Jun PMID: 27291391.
  43. Younossi ZM, Stepanova M, Charlton M, Curry MP, O’Leary JG, Brown RS, Hunt S. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016 Oct;1(2):122-132. doi: 10.1016/S2468-1253(16)30009-7. Epub 2016 Aug PMID: 28404069.
  44. Younossi ZM, Stepanova M, Henry L, Younossi I, Weinstein A, Nader F, Hunt S. Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. J Viral Hepat. 2016 Aug;23(8):623-30. doi: 10.1111/jvh.12528. Epub 2016 Mar PMID: 26988765.
  45. Younossi ZM, Stepanova M, Feld J, Zeuzem S, Jacobson I, Agarwal K, Hezode C, Nader F, Henry L, Hunt S. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016 Jul;65(1):33-39. doi: 10.1016/j.jhep.2016.02.042. Epub 2016 Mar PMID: 26956698.
  46. Younossi ZM, Stepanova M, Henry L, Nader F, Younossi Y, Hunt S. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine (Baltimore). 2016 Jul;95(28):e4151. doi: 10.1097/MD.0000000000004151. PMID: 27428205; PMCID: PMC4956799.
  47. Younossi ZM, Stepanova M, Henry L. Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. Value Health. 2016 Jul-Aug;19(5):544-51. doi: 10.1016/j.jval.2016.02.005. Epub 2016 Apr PMID: 27565271.
  48. Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. Am J Gastroenterol. 2016 Jun;111(6):808-16. doi: 10.1038/ajg.2016.99. Epub 2016 Mar PMID: 27021197.
  49. Younossi ZM, Stepanova M, Chan HLY, Lee MH, Yu ML, Dan YY, Choi MS, Henry L. Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. Medicine (Baltimore). 2016 Mar;95(9):e2702. doi: 10.1097/MD.0000000000002702. PMID: 26945356; PMCID: PMC4782840.
  50. Younossi ZM, Stepanova M, Nader F, Henry L. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin- Free Regimens. J Am Geriatr Soc. 2016 Feb;64(2):386-93. doi: 10.1111/jgs.13928. Epub 2016 Jan PMID: 26825683.
  51. Younossi I, Weinstein A, Stepanova M, Hunt S, Younossi ZM. Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity. Psychosomatics. 2016 Jan-Feb;57(1):82-8. doi: 10.1016/j.psym.2015.10.005. Epub 2015 Oct PMID: 26791515.
  52. Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, Bourlière M. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int. 2016 Jan;36(1):42-8. doi: 10.1111/liv.12886. Epub 2015 Jun PMID: 26059860.
  53. Younossi ZM, Stepanova M, Afdhal N, Kowdley KV, Zeuzem S, Henry L, Hunt SL, Marcellin P. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015 Aug;63(2):337-45. doi: 10.1016/j.jhep.2015.03.014. Epub 2015 Mar PMID: 25795586.
  54. Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015 Jun;61(6):1798-808. doi: 10.1002/hep.27724. Epub 2015 Mar PMID: 25627448.
  55. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Gerber L, Nader F, Hunt S. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec PMID: 24316172.
  56. Younossi ZM, Stepanova M, Zeuzem S, Dusheiko G, Esteban R, Hezode C, Reesink HW, Weiland O, Nader F, Hunt SL. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol. 2014 Aug;61(2):228-34. doi: 10.1016/j.jhep.2014.04.003. Epub 2014 Apr PMID:
  57. Younossi ZM, Stepanova M, Nader F, Jacobson IM, Gane E, Nelson D, Lawitz E, Hunt SL. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology. 2014 Jun;59(6):2161-9. doi: 10.1002/hep.27161. Epub 2014 Apr PMID: 24710669.
  58. Popovic DDj, Kovacevic NV, Kisic Tepavcevic DB, Trajkovic GZ, Alempijevic TM, Spuran MM, Krstic MN, Jesic RS, Younossi ZM, Pekmezovic TD. Validation of the chronic liver disease questionnaire in Serbian patients. World J Gastroenterol. 2013 Aug 14;19(30):4950-7. doi: 10.3748/wjg.v19.i30.4950. PMID: 23946600; PMCID: PMC3740425.
  59. Loria A, Escheik C, Gerber NL, Younossi ZM. Quality of life in cirrhosis. Curr Gastroenterol Rep. 2013 Jan;15(1):301. doi: 10.1007/s11894-012-0301-5. PMID: 23250701.
  60. Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy – a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011 Oct;34(8):853-61. doi: 10.1111/j.1365-2036.2011.04808.x. Epub 2011 Aug PMID: 21848797.
  61. Saab S, Bownik H, Ayoub N, Younossi Z, Durazo F, Han S, Hong JC, Farmer D, Busuttil RW. Differences in health-related quality of life scores after orthotopic liver transplantation with respect to selected socioeconomic factors. Liver Transpl. 2011 May;17(5):580-90. doi: 10.1002/lt.22268. PMID: 21506246.
  62. Ong JP, Oehler G, Krüger-Jansen C, Lambert-Baumann J, Younossi ZM. Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study. Clin Drug Investig. 2011;31(4):213-20. doi: 10.2165/11586700-000000000-00000. PMID: 21208014.
  63. Two R, Verjee-Lorenz A, Clayson D, Dalal M, Grotzinger K, Younossi ZM. A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries. Value Health. 2010 Jan- Feb;13(1):128-31. doi: 10.1111/j.1524-4733.2009.00585.x. Epub 2009 Aug PMID:
  64. Schulz KH, Kroencke S, Ewers H, Schulz H, Younossi ZM. The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ). Qual Life Res. 2008 May;17(4):575-84. doi: 10.1007/s11136-008-9332-7. PMID: 18389385.
  65. Bondini S, Kallman J, Dan A, Younoszai Z, Ramsey L, Nader F, Younossi ZM. Health-related quality of life in patients with chronic hepatitis B. Liver Int. 2007 Oct;27(8):1119-25. doi: 10.1111/j.1478-3231.2007.01558.x. PMID: 17845541.
  66. Kallman J, O’Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci. 2007 Oct;52(10):2531-9. doi: 10.1007/s10620-006-9708-x. Epub 2007 Apr PMID: 17406828.
  67. Dan AA, Kallman JB, Wheeler A, Younoszai Z, Collantes R, Bondini S, Gerber L, Younossi ZM. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2007 Sep 15;26(6):815-20. doi: 10.1111/j.1365-2036.2007.03426.x. PMID: 17767465.
  68. Saab S, Ibrahim AB, Shpaner A, Younossi ZM, Lee C, Durazo F, Han S, Esrason K, Wu V, Hiatt J, Farmer DG, Ghobrial RM, Holt C, Yersiz H, Goldstein LI, Tong MJ, Busuttil RW. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl. 2005 Feb;11(2):218-23. doi: 10.1002/lt.20345. PMID:
  69. Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol. 2000 Feb;95(2):497-502. doi: 10.1111/j.1572-0241.2000.01774.x. PMID: 10685757.
  70. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999 Aug;45(2):295-300. doi: 10.1136/gut.45.2.295. PMID: 10403745; PMCID: PMC1727607.